Q3 2025 Earnings Call November 3, 2025 4:30 PM ESTCompany ParticipantsCamilla Zuckero - Vice President of Investor ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...
Delivered Q3 2025 revenue of $83 millionQ32025 non-dermatologic revenue increased by 67% over Q32024Q32025 total test reports ...
Extended dosing of dupilumab in patients with AD has similar efficacy as standard dosing, with no significant affect seen on ocular adverse events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback